Strides Pharma Science · NSE: STAR · BSE: 532531

Q2 FY25 results · Jul–Sep 2024

Strides Pharma Science reported revenue from operations of ₹1,201.11 crore (up 20.2% from Q2 FY24) and net profit of ₹93.66 crore for Q2 FY25 (Jul–Sep 2024), on a consolidated basis.

Consolidated · ₹ crore
Item	Q2 FY25	Q2 FY24	YoY	Q1 FY25	QoQ
Revenue from operations	1,201.11	999.43	+20.2%	1,087.51	+10.4%
Other income	28.41	35.85	−20.7%	12.72	+123.4%
Total income	1,229.52	1,035.28	+18.8%	1,100.22	+11.8%
Profit before share of associates & JVs and tax	127.67	(114.64)	Turned profit	96.98	+31.7%
Share of profit/(loss) of associates & JVs	(12.81)	(42.25)		(11.80)
Net profit for the period	93.66	(149.46)	Turned profit	68.31	+37.1%
Attributable to shareholders of the company	93.23	(131.34)	Turned profit	70.20	+32.8%
EPS, basic (₹)	10.14	(14.54)	Turned profit	7.64	+32.7%
Net margin (%)	7.8	-15.0		6.3

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q2 FY25	Q2 FY24	YoY	Q1 FY25	QoQ
Revenue from operations	609.96	540.29	+12.9%	554.75	+10.0%
Other income	23.55	22.34	+5.4%	11.83	+99.0%
Total income	633.50	562.63	+12.6%	566.58	+11.8%
Profit before tax	14.43	4.19	+244.1%	5.66	+154.8%
Net profit for the period	15.31	1.28	12x	3.92	+290.6%
EPS, basic (₹)	1.66	0.14	12x	0.43	+286.0%
Net margin (%)	2.5	0.2		0.7

Consolidated

Filed with BSE: 25 Oct 2024, 15:34 IST
Board meeting: 24 Oct 2024
Period: 01 Jul 2024 to 30 Sep 2024
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 25 Oct 2024, 15:34 IST
Board meeting: 24 Oct 2024
Period: 01 Jul 2024 to 30 Sep 2024
Review status: Unaudited
Source: XBRL filing on BSE